Replimune Group, Inc.
Replimune Group, Inc. (REPL) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · REPL · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
12
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Replimune Group, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
REPL insider buying and selling by quarter
REPL insider selling · REPL insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · REPL ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
REPL executive sell shares · REPL board member insider trading · REPL insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 12,000 | $111K | Form 4 |
| May 18, 2026 | Xynos Konstantinos Chief Medical Officer | Sale | 14,023 | $71K | Form 4 |
| May 18, 2026 | Schwendenman Andrew CAO | Sale | 7,894 | $40K | Form 4 |
| May 18, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 8,626 | $44K | Form 4 |
| May 18, 2026 | Astley-Sparke Philip Director | Sale | 17,657 | $90K | Form 4 |
| May 18, 2026 | Patel Sushil CEO · Director | Sale | 37,324 | $190K | Form 4 |
| May 18, 2026 | Hill Emily Luisa CFO | Sale | 7,812 | $40K | Form 4 |
| Apr 1, 2026 | Sarchi Christopher Chief Commercial Officer | Award | 50,000 | — | Form 4 |
| Apr 1, 2026 | Astley-Sparke Philip Director | Award | 50,000 | — | Form 4 |
| Apr 1, 2026 | Xynos Konstantinos Chief Medical Officer | Award | 50,000 | — | Form 4 |
| Apr 1, 2026 | Schwendenman Andrew CAO | Award | 36,667 | — | Form 4 |
| Apr 1, 2026 | Patel Sushil CEO · Director | Award | 251,240 | — | Form 4 |
| Apr 1, 2026 | Hill Emily Luisa CFO | Award | 50,000 | — | Form 4 |
| Apr 2, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 6,500 | $52K | Form 4 |
| Feb 18, 2026 | Astley-Sparke Philip Director | Gift | 25,000 | — | Form 4 |
| Dec 19, 2025 | Patel Sushil CEO · Director | Award | 200,000 | — | Form 4 |
| Dec 19, 2025 | Xynos Konstantinos Chief Medical Officer | Award | 60,000 | — | Form 4 |
| Dec 19, 2025 | Hill Emily Luisa CFO | Award | 60,000 | — | Form 4 |
| Dec 19, 2025 | Sarchi Christopher Chief Commercial Officer | Award | 35,000 | — | Form 4 |
| Dec 19, 2025 | Schwendenman Andrew CAO | Award | 10,000 | — | Form 4 |
| Dec 9, 2025 | Dhingra Kapil Director | Option | 3,169 | $6K | Form 4 |
| Dec 9, 2025 | Dhingra Kapil Director | Sale | 3,169 | $33K | Form 4 |
| Dec 2, 2025 | Patel Sushil CEO · Director | Sale | 10,000 | $111K | Form 4 |
| Nov 17, 2025 | Sarchi Christopher Chief Commercial Officer | Sale | 5,208 | $47K | Form 4 |
| Nov 17, 2025 | Xynos Konstantinos Chief Medical Officer | Sale | 7,248 | $66K | Form 4 |
Sarchi Christopher
Chief Commercial Officer
Date
Jun 1
Shares
12,000
Price
$9.24
Value
$111K
Xynos Konstantinos
Chief Medical Officer
Date
May 18
Shares
14,023
Price
$5.08
Value
$71K
Sarchi Christopher
Chief Commercial Officer
Date
May 18
Shares
8,626
Price
$5.08
Value
$44K
Sarchi Christopher
Chief Commercial Officer
Date
Apr 1
Shares
50,000
Price
—
Value
—
Sarchi Christopher
Chief Commercial Officer
Date
Apr 2
Shares
6,500
Price
$8.01
Value
$52K
Xynos Konstantinos
Chief Medical Officer
Date
Dec 19
Shares
60,000
Price
—
Value
—
Sarchi Christopher
Chief Commercial Officer
Date
Dec 19
Shares
35,000
Price
—
Value
—
Sarchi Christopher
Chief Commercial Officer
Date
Nov 17
Shares
5,208
Price
$9.10
Value
$47K
Xynos Konstantinos
Chief Medical Officer
Date
Nov 17
Shares
7,248
Price
$9.10
Value
$66K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About REPL insider trading
REPL insider trades
Replimune Group, Inc. (REPL) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Sarchi Christopher (Chief Commercial Officer), Xynos Konstantinos (Chief Medical Officer), Patel Sushil (CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. REPL insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Replimune Group, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
REPL insider trading · 5 questionsThe insiders of Replimune Group, Inc. (REPL) include executives and directors such as Sarchi Christopher (Chief Commercial Officer), Xynos Konstantinos (Chief Medical Officer), Patel Sushil (CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026